Publication

Potential applications for sigma receptor ligands in cancer diagnosis and therapy

van Waarde, A., Rybczynska, A. A., Kuzhuppilly Ramakrishnan, N., Ishiwata, K., Elsinga, P. H. & Dierckx, R. A. J. O., Oct-2015, In : Biochimica et Biophysica Acta-Biomembranes. 1848, 10, p. 2703-2714 12 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Sigma receptors (sigma-1 and sigma-2) represent two independent classes of proteins. Their endogenous ligands may include the hallucinogen N,N-dimethyltryptamine (DMT) and sphingolipid-derived amines which interact with sigma-1 receptors, besides steroid hormones (e.g., progesterone) which bind to both sigma receptor sub-populations. The sigma-1 receptor is a ligand-regulated molecular chaperone with various ion channels and G-protein-coupled membrane receptors as clients. The sigma-2 receptor was identified as the progesterone receptor membrane component 1 (PGRMC1). Although sigma receptors are over-expressed in tumors and up-regulated in rapidly dividing normal tissue, their ligands induce significant cell death only in tumor tissue. Sigma ligands may therefore be used to selectively eradicate tumors. Multiple mechanisms appear to underlie cell killing after administration of sigma ligands, and the signaling pathways are dependent both on the type of ligand and the type of tumor cell. Recent evidence suggests that the sigma-2 receptor is a potential tumor and serum biomarker for humaniung cancer and an important target for inhibiting tumor invasion and cancer progression. Current radiochemical efforts are focused on the development of subtype-selective radioligands for positron emission tomography (PET) imaging. Right now, the mostpromising tracers are [F-18]fluspidine and [F-18]FTC-146 for sigma-1 receptors and [C-11]RHM-1 and [F-18]ISO-1 for the sigma-2 subtype. Nanoparticles coupled to sigma ligands have shown considerable potential for targeted delivery of antitumor drugs in animal models of cancer, but clinical studies exploring this strategy in cancer patients have not yet been reported. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers. (C) 2014 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)2703-2714
Number of pages12
JournalBiochimica et Biophysica Acta-Biomembranes
Volume1848
Issue number10
Publication statusPublished - Oct-2015

    Keywords

  • Antitumor agents, Chemotherapy, Drug targeting, Positron emission tomography, Sigma-1 receptor, Sigma-2 receptor, MEMBRANE COMPONENT 1, PROGESTERONE-BINDING SITE(S), TUMOR-CELL DEATH, IN-VITRO, PHARMACOLOGICAL EVALUATION, BIOLOGICAL EVALUATION, POTASSIUM CHANNELS, STEALTH LIPOSOMES, SYSTEMIC DELIVERY, SIRNA DELIVERY

ID: 15893498